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COMPARATIVE MOLECULAR CHARACTERIZATION OF TYPICAL AND
EXCEPTIONAL RESPONDERS IN GLIOBLASTOMA
Kristin Wipfler, Ph.D.
University of Nebraska, 2017
Supervisor: Chittibabu Guda, Ph.D.
Glioblastoma (GBM) is the most common and the deadliest type of primary brain tumor,
with a median survival time of only 15 months despite aggressive treatment. Although
most patients have an extremely poor prognosis, a small number of patients survive far
beyond the median survival time. Investigation of these “exceptional responders” has
sparked a great deal of interest and is becoming an important focus in the field of cancer
research. To investigate the molecular differences between typical and exceptional
responders in GBM, comparative analyses of copy number, methylation, gene expression,
miRNA expression, and protein expression data sets from The Cancer Genome Atlas were
performed, and the results of these analyses were integrated via correlation studies and
pathway analyses to assess the functional significance of the differential aberrations.
Typical responders are characterized by upregulation of NF-κB signaling and of proinflammatory cytokines and their associated pathways, while exceptional responders are
characterized by upregulation of Alzheimer’s and Parkinson’s disease pathways, as well
as of genes involved in synaptic transmission and plasticity. The upregulated pathways
and processes in typical responders are consistently associated with more aggressive
tumor phenotypes, while those in the exceptional responders suggest a retained ability in
tumor cells to undergo cell death.
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INTRODUCTION

Glioblastoma
Glioblastoma (GBM) is the most common and the deadliest type of primary brain
tumor. GBM is highly malignant and nearly uniformly fatal, with a median survival time
of only approximately 15 months despite aggressive treatment, including surgical
resection followed by concurrent radiation and chemotherapy with temozolomide. 1–3
GBM tumors are particularly aggressive due to their high degree of heterogeneity and
tentacle-like projections that infiltrate surrounding brain tissue, making them extremely
difficult to fully excise.4,5
The central nervous system is comprised of neurons and glia (including astrocytes,
oligodendrocytes, and microglia).6 GBM arises from astrocytes, star-shaped glial cells that
play a variety of diverse roles in the central nervous system, including maintenance of
homeostasis, regulation of blood flow, and synaptic transmission.5,7 GBM usually arises
in the cerebral hemispheres, but can be found anywhere in the brain or spinal cord. Most
cases occur sporadically, without genetic predisposition. The only known risk factors are
some specific genetic diseases (neurofibromatosis, tuberous sclerosis, Li-Fraumeni
syndrome, retinoblastoma, and Turcot syndrome) and some environmental exposures
(ionizing radiation, vinyl chloride, pesticides, smoking, petroleum refining, and synthetic
rubber manufacturing). The most common symptom is a progressive neurological deficit
resulting in personality changes or memory loss, but headaches and seizures may occur
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as well. The incidence of GBM is higher in men than in women and presents at a median
age of 64 years.2
There are three pathways that are consistently dysregulated in GBM: the p53
pathway, the receptor tyrosine kinase/Ras/phosphoinositide 3-kinase signaling pathway,
and the retinoblastoma pathway. Other common alterations include overexpression of
EGFR (epidermal growth factor receptor), mutations in PTEN (phosphatase and tensin
homolog), and loss of chromosome 10.2 Treatment options targeting these genes and
pathways have been explored, primarily anti-EGFR agents, but their efficacy is limited by
drug resistance.8

The Cancer Genome Atlas
The Cancer Genome Atlas (TCGA) was a project led by the National Cancer
Institute (NCI) and the National Human Genome Research Institute that began in 2005. It
was a database that contained genomic data obtained from a variety of high-throughput
genome analysis techniques for 33 different cancer types. Data types investigated in the
TCGA project included gene expression profiling, copy number variation, SNP
genotyping, DNA methylation profiling, and many more. The primary goal of the project
was to demonstrate that genomic data from a variety of sources could be integrated and
utilized to identify statistically and biologically significant alterations in cancer.9,10
The TCGA project has now concluded, but the more than two petabytes of
genomic data generated in the project have been made publicly available through the
Genomic Data Commons (GDC). This massive amount of data provides a unique
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opportunity to analyze a variety of data types for a large number of cancer patients. By
the end of the TCGA project, the GBM dataset included data for 528 patients. The different
data types included in the GBM dataset were clinical information, gene expression, exon
expression, miRNA expression, copy number arrays, methylation arrays, SNP arrays,
trace files, somatic mutations, protein expression, and RNAseq (Table 1).10–12

Exceptional Responders Initiative
With the end of the TCGA project, NCI is now developing multiple new genomics
databases, one of which is the Exceptional Responders Initiative (ERI). The goal of this
project is to identify molecular features that predict whether or not a particular drug or
class of drugs will help patients live longer. In many cases, a treatment is deemed
unsuccessful after a clinical trial, but 10% or fewer of the patients still have a favorable
response. The ERI project intends to identify markers that predict positive responses in
such cases. The database will include patients that receive standard treatments as well,
not just patients in clinical trials.13,14
The idea for the ERI came about based on the concept of exceptional responders,
patients who have a unique response to treatments that are not effective for most other
patients. The exact definition of “exceptional” varies by specific disease, stage, and
treatment. In general, exceptional responders achieve a complete or partial response that
only up to 10% of patients experience, and they sustain that response for a much longer
duration than the median response.13–15
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Data Type

N (full dataset)

N (subset)

Clinical

499

75

Copy Number (SNP array)

493

72

Methylation (27k)

287

32

Gene Expression (DNA microarray)

440

67

miRNA Expression

474

72

Protein Expression

210

20

Table 1: Number of patients in each data type in the TCGA GBM dataset. Of the data types
available for GBM, seven were analyzed, six of which are discussed in this dissertation. The
number of patients for each of these data types is listed for the full dataset (499 Total) as well as for
the dataset analyzed in this work (75 total). The selection of this subset of patients is discussed in
Chapter 1. The exon expression and copy number array data types were excluded due to
redundancy with gene expression and SNP arrays, respectively. RNAseq was excluded because
the available data files were highly processed with a methodology that is not preferred, while the
gene expression data type was available in a raw format. Trace files were excluded as they are
outdated, having a been replaced by GAM files. When data were available from multiple platforms
for a single data type, the most comprehensive option was chosen for analysis whenever possible.
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Investigating these exceptional responders has become an important focus for the
future of cancer research. There is a great deal of interest in studying these rare patients
to learn how to improve therapies for patients who have a more typical response. Several
studies of exceptional responders have already been published, and they have helped
uncover molecular alterations and mechanisms of resistance. With the huge amount of
interest and funding being directed at this topic, it is expected that studies of exceptional
responders will be a major focus of cancer research in the near future.16–19

Hypothesis
Analyzing and integrating the information from the variety of next generation
sequencing and array-based data available in TCGA (now the GDC) for typical and
exceptional responders will reveal aberrations that produce more aggressive tumors in
typical responders as well as protective effects in exceptional responders. This will
provide a clearer picture of the molecular basis of GBM and also reveal possible
therapeutic targets and markers for a positive or negative response to standard therapy.
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CHAPTER 1
SURVIVAL ANALYSIS AND DEFINING THE RESPONSE GROUPS

Introduction
With current therapies, the median survival time for GBM patients is
approximately 15 months. Although most patients have an extremely poor outcome, a
small number of patients survive far beyond the median survival time.1 Survival analyses
in the current literature often have a very small sample size and look specifically at a very
small set of genes, such as IDH1 and MGMT or EGFR and TP53.20–23 These studies often
have arbitrarily chosen survival time cutoffs, typically >36 months for long survival and
<36 months for short survival. These cutoffs are not appropriate for the study of survival
outcomes in GBM, as the resulting short survival groups would include many patients
who survive well beyond the median survival time. Defining survival groups to compare
based on specific characteristics of GBM and the survival curve of TCGA GBM patients
would be a vast improvement over the commonly used arbitrary methods described
above.
In addition to an improved method of defining survival groups, a main focus of
this study is an investigation of so-called “exceptional responders” in GBM. NCI
researchers conducting the ERI study define exceptional responders as “patients who
have dramatic and long-lasting responses to treatments for cancer that were not effective
for most similar patients.” The precise definition of exceptional is specific to the disease,
stage, and treatment.13–15 For GBM, defining what constitutes an exceptional response may
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be more straightforward than for most cancers, since all primary GBM tumors are
classified as grade IV and most patients receive the same standard treatment of tumor
resection followed by radiation and chemotherapy with temozolomide. The response to
this treatment is also very consistent, with most patients surviving very close to the
median survival time and a relatively small number of patients surviving a substantially
longer time.1–3
Due to the shortcomings in the methodology of defining survival groups in
current GBM studies, there is a need for a GBM survival analysis utilizing cutoff
parameters specific to characteristics of this disease. With the recent shift of focus to
exceptional responders in cancer research, it is also important to incorporate this concept
into survival studies in cancer, particularly in cancers like GBM, where most patients
respond poorly to treatment but an exceptional few respond very positively. This study
addresses both of these needs, utilizing an improved method of defining survival groups
guided by the concept of exceptional responders.

Methods
Inclusion criteria were applied utilizing clinical information contained within the
TCGA Biotab files for GBM. Only untreated primary GBM samples from patients with
known survival times were included in the survival analysis. A Kaplan-Meier survival
curve was generated based on the survival times of the patients remaining after the
application of the inclusion criteria. The top 10% of patients with the longest survival
times were designated as “exceptional responders.” The 10% cutoff was chosen based on
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the survival curve and loosely based on the ERI definitions of exceptional responders. 15
The median 10% of patients were classified as “typical responders” in order to have
comparable sample sizes between the two groups. Linear regression models were
generated with XLSTAT to investigate possible confounding variables that may influence
survival, including sex, race, ethnicity, diagnosis method, age, and Karnofsky score. The
term with the highest non-significant p-value was removed and the model was
regenerated until the overall model and each term were significant (p < 0.05). An age
cutoff was applied and linear regression models were generated again using the reduced
number of samples in order to identify any remaining confounding variables.

Results
After the application of the inclusion criteria, 408 patients remained in the dataset.
The Kaplan-Meier survival curve (Figure 1) for those 408 patients shows a steep drop in
the first two years, with the survival time for the vast majority of patients within one year
of the median 345 days. The curve levels off between two and three years, and a relatively
small number of patients survive beyond that time. The patients within that range are in
roughly the top 10% for survival time, which was the defining factor for the exceptional
responders group.
Age and sex were determined to be confounding variables in the linear regression
models. An age cutoff of ≥30 years was applied, which reduced the exceptional responders
group by five patients and corrected for the confounding variable of age. Ethnicity was
the same for all patients in this group (not Hispanic or Latino) and Karnofsky score, age,
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Figure 1: Survival curve for TCGA GBM dataset. This curve includes the 408 TCGA GBM patients
that met the inclusion criteria. The curve is characterized by a steep drop off centered around the
median of 345 days, with a small number of patients surviving beyond approximately 2.5 years.
Typical responders are labeled in blue and exceptional responders are labeled in green.
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race, and diagnosis method were not significant predictors of survival time. However, sex
was predictive of outcome, with female patients enriched in the exceptional responders
group (regression model p=0.021, chi-squared test p=0.034). Sex is only associated with
survival in the typical and exceptional response groups, not in the full dataset of 408
patients.
The final dataset included 40 typical responders and 35 exceptional responders
(Table 2). Males are more highly represented in the typical response group, and the
exceptional responders tend to be a bit younger with a mean age of 49.8 years compared
to the typical responders’ mean age of 58.7 years. However, this age difference is not
statistically significant. The median survival for the typical group is the same as the full
dataset (345 days) with a range of 320-378 days. Median survival for the exceptional group
is 1282 days (approximately 3.5 years) with a range of 864-3881 days (approximately 2.410.6 years).

Discussion
Although the current median survival time for GBM is approximately 15 months,
the 12 month median in the full dataset and the typical responders group is consistent
with the time period in which most of these samples were obtained.24 The characteristics
of the survival curve are as expected based on previous GBM survival studies.
While the confounding variable of age was addressed with an age cutoff, the only
way to fully address the confounding variable of sex is to completely exclude either males
or females from the study. Rather than sacrificing such a large number of samples and
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Table 2: Descriptive statistics for the full dataset and response groups. Statistics on sample size,
age, and survival time are included for the full group of patients that met the inclusion criteria as
well as for the typical and exceptional response groups. Typical responders closely resemble the
norm for GBM in general, while exceptional responders tend to be younger (though this is not
statistically significant) and have an equal representation of males and females as opposed to the
usual higher proportion of males (this is statistically significant).
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restricting the relevance of this study to only one sex, this issue was addressed in each
individual analysis for all data types, as described in subsequent chapters.
In order to ensure that no samples in the study had been exposed to radiation or
other treatments that may corrupt results, only untreated tumor samples were included
in the dataset. The dataset also includes only primary GBM samples in order to avoid
statistical noise from secondary GBM samples, which develop through progression of
low-grade astrocytomas and should be approached as a different disease.25
The typical and exceptional response groups defined in this chapter were utilized
throughout the entirety of this study.
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CHAPTER 2
COPY NUMBER

Introduction
A variety of copy number variations have been identified in GBM, the most
prevalent of which is amplification of chromosome 7, particularly of EGFR.26–28 Other
frequently occurring copy number changes include losses of chromosomes 9p
(particularly of CDKN2A, cyclin-dependent kinase inhibitor 2A)26,28,29 and 1026,27,29 as well
as gains in chromosomes 19 and 2026,30. Some studies have associated these copy number
alterations with prognosis, while others have determined that they are not significantly
associated with outcome.27,30–32
Copy number alterations across the genome can be assessed with comparative
genomic hybridization (CGH) arrays as well as single nucleotide polymorphism (SNP)
genotyping arrays. The Affymetrix Genome-Wide Human SNP Array 6.0, which was the
type of array utilized in this study, assesses more genetic variation than any other array.
It includes over 1.8 million markers, including over 946,000 probes that detect copy
number variation.33

Methods
Affymetrix Genome-Wide Human SNP Array 6.0 CEL files were obtained from
the GDC Legacy Archive on April 15, 2017 for 38 typical and 34 exceptional responders
(Table 3). The files were divided into four groups based on response group and sex and
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Typical

Exceptional

Female

11

17

Male

27

17

Table 3: Sample number by sex and response group in copy number analysis. Nearly all of the
patients in the two response groups had copy number data available. As expected, there is a higher
proportion of males in the typical response group and an equal number of males and female in the
exceptional response group.
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processed with the R tool Rawcopy.34 Log2 ratio values (relative to normal) obtained from
the genelist files generated by Rawcopy were compared between typical and exceptional
responders to identify any differential gains or losses. A log2 ratio cutoff of +/- 0.25 was
used to define a copy number gain/loss, and only probes where the mean log2 ratio
indicated a gain or loss for at least one of the response groups were included in the
analysis. An additional cutoff was applied in which the difference in the mean log2 ratio
between typical and exceptional responders must be > 0.2. Redundant probes (probes for
the same gene with the same log2 ratio value) were removed. Welch’s unequal variances
t-tests were performed for each remaining probe and a multiple testing correction was
performed using the Benjamini-Hochberg false discovery rate (FDR) method (q < 0.1). This
process was repeated for sex-specific analyses (typical male versus exceptional male and
typical female versus exceptional female) with sex chromosomes excluded. A subset of
results from this analysis were investigated with respect to the distribution of gains/losses
and amplifications/deletions (log2 ratio cutoff +/- 0.8) between typical and exceptional
responders. Significance was determined with chi-squared tests (p < 0.05) when the
distributions of gains/amplifications and losses/deletions were compared.

Results
Copy number heatmaps for each patient (Figure 2) show consistent alterations
regardless of response group or sex. These include gains in chromosomes 7, 19, and 20 as
well as losses in chromosomes 9p, 10, 13, and 14, all of which have been described
previously in the literature.26–32 A plot of the mean log2 ratios across the genome for each
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Figure 2: Copy number heat maps by sex and response group. Heat maps generated by Rawcopy
for typical and exceptional responders, separated by sex. For each response group, female patients
are grouped above and male patients are grouped below. All groups are characterized by gains in
chromosomes 7 (particularly around EGFR in 7p), 19, and 20 as well as losses in chromosomes 9p
and 10.
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response group (Figure 3) also indicates that those gains and losses occur consistently in
both response groups, although the magnitude of the gain or loss typically appears to be
greater in typical responders.
The Rawcopy analysis generates log2 ratios relative to normal for each probe in each
array. After applying the cutoffs described above to the mean log2 ratios for each response
group, 10 probes associated with alterations at 10 genes remained. Following the t-tests
and multiple testing correction, 5 of these were determined to be differentially altered
between the response groups (Table 4). The 5 genes identified are the olfactory receptors
OR4M2 (p = 0.018) and OR4N4 (p = 0.022), as well as LOC285878 (p = 0.026), VSTM2A (p
= 0.025), and CDKN2A-AS1 (p = 0.048). VSTM2A and LOC285878 were both characterized
by gains, while OR4M2, OR4N4, and CDKN2A-AS1 were characterized by losses. The
sex-specific analyses did not yield any significant results.
Utilizing a log2 ratio cutoff of +/-0.25 to define copy number gains/losses, several
regions as well as specific genes were identified as altered relative to normal (Table 4).
Most of these changes have already been implicated in GBM, and most of them were not
significantly differentially altered between typical and exceptional responders. These
included gains in chromosome 7p (Figure 4), losses in chromosome 9p (Figure 5), losses
in chromosome 13q, and losses across the entirety of chromosome 10. Smaller regions of
altered copy number included losses at LCE3C, ADAM3A, OR52N5, OR4M2, and OR4N4
as well as gains at FKBP9, PRSS3P2, AND PRSS2.
Based on three of the genes identified as significantly differentially altered
between the two response groups, in combination with regions of gain/loss that were
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Figure 3: Genome-wide mean copy number for each response group. Mean log2 ratios assessed
at approximately 40,000 probes are shown in blue for typical responders and green for exceptional
responders across the genome, excluding sex chromosomes. The most prominent alterations are
gains in chromosome 7 and losses in chromosomes 9p and 10. Peaks tend to be of a greater
magnitude in the typical response group.
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Gains
Region and Gene(s)
7p11.2
HPVC1, VSTM2A*, LOC285878*, SEC61G,
EGFR, EFGR-AS1, LANCL2, VOPP1, FKBP9L,
SEPT14, MRPS17, GBAS, PSPH, CCT6A,
SNORA15, SUMF2, PHKG1, CHCHD2, and
NUPR1L
7q21.2
AKAP9, CYP51A1, LRRD1, KRIT1, ANKIB1,
GATAD1, PEX1, RBM48, MGC16142,
FAM133B, and CDK6
7q34
PRSS3P2 and PRSS2

Response Group Affected

typical; exceptional to a lesser extent

typical

typical

Losses
Region and Gene(s)
1q21.3
LCE3C
8p11.22
ADAM3A
9p21.3, 9p21.2
FOCAD, MIR491, PTPLAD, IFNB1, IFNW1,
IFNA21, IFNA4, IFNA7, IFNA10, IFNA16,
IFNA17, IFNA14, IFNA22P, IFNA5, KLHL9,
IFNA6, IFNA13, IFNA8, IFNA1, MIR31HG,
IFNE, MIR31, MTAP, CDKN2A-AS1*,
CDKN2A, CDKN2B-AS1, CDKN2B,
DMRTA1, FLJ35282, ELAVL2, IZUMO3,
TUSC1, LOC100506422
entirety of chromosome 10
11p15.4
OR52N5
13q14.2
DLEU2, MIR16-1, MIR15A, DLEU1, and
ST13P4
15q11.2
OR4M2* and OR4N4*

Response Group Affected
exceptional
typical

typical; exceptional to a lesser extent

typical and exceptional
typical
exceptional
exceptional

Table 4: Regions of copy number gain and loss. Regions of copy number gain (mean log2 ratio >
0.25) and loss (mean log2 ratio < -0.25 ) are shown with lists of specific genes affected in each region.
The affected response group is described for each region. Genes in bold and labeled with a *
reached statistical significance based on t-tests comparing typical and exceptional responders.
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Figure 4: Copy number gain in 7p11.2. Mean log2 ratios for typical (blue) and exceptional (green)
responders in the region of chromosome 7p11.2 described in Table 3. Both groups are characterized
by gains (log2 ratio > 0.25) and amplifications (log2 ratio > 0.8) in this region, but the magnitude is
greater in typical responders. VSTM2A and VSTM2A-OT1 (marked with stars) have differential
copy numbers between the two groups that reach statistical significance.
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Figure 5: Copy number loss in 9p21.2 and 9p21.3. Mean log2 ratios for typical (blue) and
exceptional (green) responders in the region of chromosome 9p21 described in Table 3. Both groups
are characterized by losses (log2 ratio < -0.25) in this region, but the magnitude is generally greater
in typical responders. CDKN2A-AS1 (marked with a star) has differential copy numbers between
the two groups that reach statistical significance.
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found, EGFR and CDKN2A/B were investigated more closely due to their proximity to
VSTM2A, LOC285878, and CDKN2A-AS1 as well as their previously established
relevance to GBM.35 Chi-squared tests examining the distribution of gains/amplifications
and losses/deletions among all patients in each response group indicate that typical
responders are more likely than exceptional responders to experience loss or deletion of
CDKN2A. The distributions of EGFR gain/amplification and CDKN2B loss/deletion were
not significantly different between the response groups.
Of the 1812 probes that meet the definition of copy number gain/loss, 1752 of them
are losses, and 1201 of those have a greater magnitude in typical responders. Only 60
probes indicate copy number gains, and the magnitude is greater in typical responders
for all 60 of them. Overall, 69.6% of the alterations have a larger magnitude in typical
responders.

Discussion
Defining Cutoff Values
There is no standardized log2 ratio cutoff to define copy gain and loss or
amplification and deletion. However, a cutoff of ±0.25 for gain/loss and ±0.8 for
amplification/deletion is commonly utilized for copy number studies in cancer, which is
why those definitions were applied in this study.36–38
The vast majority of log2 ratios in this study are between 0 and 1, making a fold
change cutoff at worst misleading and at best uninformative. Rather than apply a fold
change cutoff to identify regions of differential copy number alterations between the
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response groups, a cutoff was applied in which the absolute value of the difference
between the mean log2 ratios for typical and exceptional responders must be greater than
0.2. This is the same value that is typically chosen for a Δβ cutoff in methylation studies,
which also have values between 0 and 1.39–41

Differentially Altered Genes Between the Response Groups
Two of the significantly differentially altered genes identified were olfactory
receptors. This is likely an artifact and not actually associated with survival in GBM,
because there is huge variation in copy number in the general population for
approximately 50% of olfactory receptors.42
The other significant results include LOC285878 and VSTM2A, both of which are
immediately upstream of EGFR, and CDKN2A-AS1, which overlaps slightly with
CDKN2A and precedes CDKN2B. It is likely that these genes are significantly
differentially altered between the response groups due to their very close proximity to
EGFR and CDKN2A/B. Copy number alterations in GBM in both of those regions are very
well characterized. It is for this reason that those genes were investigated further. Chisquared tests indicate that loss or deletion of CDKN2A is more likely to occur in typical
responders than in exceptional responders, suggesting that copy number alteration of
CDKN2A could serve as a prognostic factor in GBM, associated with a poorer outcome.
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Other Gains and Losses
Several regions of copy number gain or loss relative to normal were identified in
this analysis. Most of these met the definition of gain or loss for one response group and
not the other, but did not reach statistical significance. Nevertheless, these may still be of
clinical interest and are worth further exploration in larger studies in the future. Some of
these alterations include loss of LCE3C, MIR16-1, MIR15A, and ST13P4 in exceptional
responders, loss of ADAM3A in typical responders, and gain of PRSS2 in typical
responders. Upregulation of MIR16 and MIR15a is associated with adverse prognosis and
poor overall survival in multiple myeloma.43 Loss of these miRNAs in exceptional
responders suggests reduced expression and lower tumorigenic potential in that response
group. PRSS2 (protease, serine 2) is thought to play a role in tumor invasion in multiple
cancers44–46 and may be contributing to more aggressive tumors in typical responders.

Rates of Gains and Losses
Losses occurred much more frequently than gains in both response groups, and
these alterations were consistently of a higher magnitude in typical responders (Figures
3, 4, and 5; Table 4). This is consistent with previous studies showing that losses occur
more frequently than gains in GBM, as well as cancers in general. This suggests that
typical responders have more frequent or more severe copy number alterations, possibly
contributing to more aggressive tumors and a poorer prognosis.
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CHAPTER 3
METHYLATION

Introduction
Methylation and β Values
DNA methylation is an epigenetic mechanism in which a methyl group is added
to a CpG site in the DNA. Methylation is typically associated with gene silencing,
particularly when the CpG site is located within a promoter.47 The level of methylation at
any given site is reported as a β value, which is the ratio of intensities between methylated
and unmethylated alleles. This value ranges from 0 (unmethylated) and 1 (fully
methylated). A β value greater than 0.7 is indicative of hypermethylation, while a β value
under 0.3 is defined as hypomethylation.48–50
In glioblastoma, a recurrent methylation aberration occurs in the promoter for
MGMT (O-6-methylguanine-DNA methyltransferase). Methylation in this region silences
expression of MGMT, which leaves tumor cells susceptible to alkylating agents.
Methylation of MGMT is therefore a marker of a positive response to chemotherapy
treatment with temozolomide in GBM.51

HumanMethylation27 Array
The HumanMethylation27 array utilizes Infinium genotyping technology to assess
the methylation level at 27, 578 CpG sites covering 14,495 genes. This method begins with
bisulfite conversion, which converts unmethylated cytosine into uracil and leaves
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methylated cytosine alone. The DNA is then amplified, and uracil is matched with
adenine, which then pairs with thymine for subsequent replications. The DNA is then
hybridized to a chip, which has two probes for each locus (one for the methylated version
and one for the unmethylated version). The different probes are then stained with
different fluorescent agents and the level of methylation is determined with the
calculation of β values.48,52

Methods
Illumina HumanMethylation27 idat files were acquired from the GDC Legacy
Archive on September 27, 2016 for 16 typical responders and 16 exceptional responders
(Table 5). The analysis was performed with RnBeads, an R package designed to perform
an analysis of DNA methylation at single nucleotide resolution in a more comprehensive
manner than other methylation tools.53 The arrays were normalized with the beta-mixture
quantile normalization method and the Greedycut algorithm was utilized for filtering.
RnBeads includes a module that addresses batch effects. There was not an adequate
number of samples to complete separate analyses to address the confounding variable of
sex. Sex chromosomes were not included in the analysis to address this issue. The
resulting lists of CpG sites and promoters were narrowed further with a Δβ (the absolute
value of the difference between the mean β value for each response group) cutoff of 0.2,
which is a commonly used cutoff for studies of differential methylation.39–41

The

Benjamini-Hochberg multiple testing correction54 was performed (q < 0.1) to identify
differentially methylated sites and promoters. The “normal” dataset was obtained from a
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Typical

Exceptional

Female

3

13

Male

10

6

Table 5: Sample number by sex and response group in methylation analysis. Nearly half of
patients had methylation data available. The distribution of sex in this group does not follow the
proportions of the full response groups, with nearly all of the typical responders being male and
nearly all the exceptional responders female, rather than a slight male majority and an even split,
respectively. Because of this, there was an insufficient sample size for sex-specific analyses.
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2013 study on methylation in neuronal and glial cells in which Illumina
HumanMethylation450 experiments were performed for non-neuronal cells of 6 different
subjects, with 2 experiments for each subject.55 Mean β values were calculated from the
signal intensities for all 12 sets. Kolmogorov-Smirnov (KS) tests were performed to
compare the distributions of beta values for typical, exceptional, and normal groups.

Results
The RnBeads report includes a differential methylation file comparing the mean
degree of methylation between the typical and exceptional response groups at each of the
approximately 27,000 CpG sites assessed by the Illumina assay. After applying the cutoffs
and a multiple testing correction, 41 differentially methylated CpG sites corresponding to
37 unique genes were identified (Table 6), 39 of which had a higher degree of methylation
in the exceptional response group. A modified volcano plot (Figure 6) indicates which of
these sites are outliers with the highest Δβ values and the lowest p values, with PCDHB12
(protocadherin beta 12), LY6K (lymphocyte antigen 6 family member K), and NKX2-5
(NK2 homeobox 5) among the top results.
The RnBeads report also includes a differential methylation file comparing the
mean degree of methylation across promoter sites between the two response groups. In
this case, data from multiple CpG sites in the same promoter (1.5 kb upstream and 0.5 kb
downstream of the transcription start site) are combined to reflect the overall methylation
level across the region. Utilizing the same cutoffs and multiple testing correction from the
site analysis, 5 differentially methylated promoters, all with a higher degree of
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cgid
cg12343638
cg08569678
cg12052765
cg03294619
cg21480743
cg04369341
cg11532513
cg17651821
cg25957124
cg01888566
cg23519022
cg24101578
cg25946389
cg25509184
cg09522147
cg10303487
cg09595479
cg18676237
cg12558519
cg26980692
cg00949442
cg24264506
cg16363586
cg27090216
cg13067215
cg20050826
cg21215336
cg12981137
cg01009664
cg09160477
cg07753583
cg07952391
cg23244913
cg12177743
cg06274159
cg25057743
cg07260592
cg17965019
cg17860158
cg12768605
cg00630164

gene name
PCDHB12
LY6K
CHAT
NKX2-5
PTEN
C20orf100
LRTM1
HIST1H4L
DNAH3
MEST
CAPZB
CDH22
MGMT
CFTR
KRT7
DPYS
PRPH
SERPINB9
KLHL26
SLC15A3
ABCA3
TTC12
BST2
TNFRSF10C
CGI-38
K6IRS2
LRRC8E
MGMT
TRH
SUSD3
LRRC61
FLJ10916
HCG9
TTC12
ZFP42
PTHR2
LPA
HIST1H3J
CNTN2
LYPD5
KCNQ4

mean β exceptional
0.5078026
0.441856355
0.351379153
0.363597909
0.381009425
0.63529373
0.406058029
0.513744205
0.705059137
0.74056681
0.534783267
0.618165843
0.394523362
0.600842388
0.588742794
0.431869687
0.732006613
0.474358981
0.34932085
0.401463369
0.424217955
0.455964348
0.679897957
0.323192125
0.317780555
0.412443387
0.595433055
0.376274797
0.460950967
0.274926433
0.62589652
0.409459146
0.543443874
0.331577699
0.630768539
0.385272981
0.653635527
0.352617133
0.394115837
0.498629758
0.489497043

mean β typical
0.262902748
0.178005278
0.140280129
0.088957022
0.18046069
0.426659616
0.630219234
0.256118974
0.476860941
0.521977296
0.74339535
0.406560371
0.179592629
0.382027484
0.36717856
0.181799459
0.52721146
0.201989707
0.099339316
0.190110148
0.221278093
0.192059252
0.474140835
0.115625389
0.106700898
0.211270568
0.390559013
0.150035143
0.249015311
0.067484552
0.417196705
0.184952884
0.332649804
0.116007362
0.422974537
0.183412711
0.435082623
0.142842183
0.183061088
0.298008361
0.277459749

Δβ
0.244899925
0.263851077
0.211099024
0.274640887
0.200548735
0.208634114
0.224161205
0.257625231
0.228198195
0.218589514
0.208612083
0.211605472
0.214930733
0.218814904
0.221564233
0.250070228
0.204795153
0.272369273
0.249981535
0.211353221
0.202939862
0.263905096
0.205757122
0.207566736
0.211079656
0.201172819
0.204874042
0.226239654
0.211935657
0.207441881
0.208699815
0.224506262
0.21079407
0.215570337
0.207794002
0.201860269
0.218552904
0.20977495
0.21105475
0.200621398
0.212037294

p value
0.000792036
0.000901718
0.001210066
0.001724144
0.00232438
0.002811554
0.002811802
0.003395508
0.003418798
0.003421299
0.003806896
0.003809712
0.003829408
0.004066663
0.004232271
0.006518306
0.007883096
0.009013391
0.009626013
0.010153909
0.012334811
0.013005415
0.01303555
0.013564396
0.01374847
0.014985767
0.016306681
0.017000628
0.018029927
0.01810372
0.01842675
0.018626547
0.018700098
0.019122814
0.019292771
0.022032263
0.022092278
0.024151396
0.025666055
0.033938924
0.042287698

Table 6: Significantly differentially methylated CpG sites. These 41 CpG sites were determined
to be differentially methylated between typical and exceptional responders following a Δβ cutoff
of 0.2 and multiple testing correction (q < 0.1). The raw p values are shown.
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Figure 6: Modified volcano plot of significantly differentially methylated CpG sites. This
includes the 41 CpG sites listed in Table 5. Each axis is skewed to reflect the cutoffs made to assess
significance (p < 0.05 and Δβ > 0.2). Sites with a lower degree of methylation in typical responders
are shown in blue and sites with a lower degree of methylation in exceptional responders are
shown in green. Sites in the upper right hand side have the largest Δβ values and the smallest p
values. Outliers and both green sites are labeled with their associated gene name.
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methylation in exceptional responders, were identified (Table 7). These include SLC15A3
(solute carrier family 15 member 3), TTC12 (tetratricopeptide repeat domain 12), LRRC8E
(leucine rich repeat containing 8 family member E), SUSD3 (sushi domain containing 3),
and LRRC61 (leucine rich repeat containing 61).
There are 45 CpG sites with a Δβ value greater than 0.2 between the typical and
exceptional response groups, 41 of which are also present in the normal dataset.
Histograms for each of these groups (Figure 7) show larger proportions of
hypomethylated (β < 0.3) sites in the typical and normal groups and more moderate β
values in the exceptional group. This observation was investigated further with KS tests
and cumulative distributions plots for each group (Figure 8). There is no difference in the
distribution of β values between typical responders and normal glial cells (p=0.127), but
the exceptional response group β value distribution is significantly different from both of
the other groups (p<0.0001 in both cases). The D statistic (a measure of the magnitude of
the difference between two datasets) is 0.622 for the typical versus exceptional comparison
and 0.734 for the normal versus exceptional comparison.

Discussion
Addressing the Confounding Variable
The distribution of sex between the typical and exceptional response groups is
quite skewed in the methylation dataset. For the other data types in this study, analyses
were typically performed three times: once for typical versus exceptional responders
overall, and then one analysis for each sex in order to address the confounding variable.
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gene name

mean β exceptional

mean β typical

Δβ

combined p value

SLC15A3

0.401463369

0.190110148

0.211353221

0.010153909

TTC12

0.393771023

0.154033307

0.239737716

0.01224649

LRRC8E

0.595433055

0.390559013

0.204874042

0.016306681

SUSD3

0.274926433

0.067484552

0.207441881

0.01810372

LRRC61

0.62589652

0.417196705

0.208699815

0.01842675

Table 7: Significantly differentially methylated promoters. The promoters of these five genes
were determined to be differentially methylated between typical and exceptional responders
following a Δβ cutoff of 0.2 and multiple testing correction (q < 0.1), based on the degree of
methylation of all the CpG sites that fall within the promoter range (1.5 kb upstream and 0.5 kb
downstream of the transcription start site) for each gene. The raw combined p values are shown.
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Figure 7: Histograms of β values in normal glial cells and each response group. The response
group histograms include mean β values for the 45 CpG sites with Δβ values larger than 0.2, and
the normal histogram includes β for 41 of those sites (the remaining 4 were not assessed in the
normal arrays). The distribution of β values in typical responders closely resembles the normal
distribution, while the exceptional responders are characterized by a shift towards larger β values.
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Figure 8: KS tests and cumulative distribution plots of β values. KS tests indicate that the
distribution of β values for the CpG sites with Δβ > 0.2 is significantly different from both the
typical and normal distributions (p < 0.0001). There is no difference between the distributions for
the typical and normal groups. Cumulative distribution plots are shown for each of the three
groups, indicating a clear shift in exceptional responders toward higher β values. The D statistic, a
measure of the magnitude of the difference between two datasets, is shown for each comparison
at the point of greatest difference. The distance between the exceptional and normal distributions
is slightly larger than the distance between the typical and normal distributions.
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In the case of methylation, this was not possible due to an insufficient number of samples.
Instead, sex chromosomes were removed from the analysis in an effort to control for
methylation differences between sexes. When this step was not taken, 44% of significant
sites and 57% of significant promoters were on the X chromosome, which was likely due
to X-inactivation and the large difference in the number of female patients between the
response groups. This method seems to have been effective as many of the results are
associated with GBM specifically or with other cancers and are often prognostic factors.

Determination of an Appropriate Δβ Cutoff
A log2 fold change cutoff is not appropriate for comparing β values since they are
all between 0 and 1 and very large fold change values could result from very small
changes in beta values, and vice versa. Instead, a Δβ cutoff was applied. A cutoff value of
0.2 was selected based on the literature and on the 27k assay technology. Most methylation
studies that use Δβ values select 0.2 as the cutoff39–41, and the Infinium I technology used
in the HumanMethylation27 arrays can detect a Δβ of approximately |0.2| with 99%
confidence.56

Differentially Methylated Regions
Although there are many genes implicated in the site-specific analysis that did not
appear in the results of the promoter analysis, this does not necessarily indicate that the
site-specific results are not important. There are many more CpG sites than the 27k
technology assesses, so it is entirely plausible that the promoters for those genes have

36

more sites that are differentially methylated between the response groups that simply
were not interrogated with the 27k arrays. A similar study with data from the Illumina
450k or EPIC (which assesses methylation status at over 850,000 CpG sites) platform
would be a significant improvement. Unfortunately, there was not a sufficient number of
patients that had 450k results to perform such an analysis.
As expected, MGMT was present in the results and is characterized by a higher
level of methylation in exceptional responders. Several other genes present in the top
results with a higher degree of methylation in exceptional responders are associated with
cancer prognosis and/or treatment response, including LY6K (lymphocyte antigen 6
family member K)57,58, DPYS (dihydropyrimidinase)59, and SERPINB9 (serpin family B
member 9)60,61. The reduced methylation of those genes in typical responders suggests
increased transcription, and expression of each of those genes is associated with more
aggressive tumors in various cancers.
Only two of the significantly differentially methylated sites had a higher level of
methylation in typical responders. Those two sites are associated with the genes CAPZB
(capping actin protein of muscle Z-line beta subunit) and LRTM1 (leucine rich repeats and
transmembrane domains 1). LRTM1 is not well-characterized, but CAPZB is known to be
an actin-capping protein that plays a role in cell morphology and differentiation. CAPZB
is a metastasis-suppressor in hepatocellular carcinoma62 and its lower methylation levels
in exceptional responders suggest that it may be more highly expressed than it is in typical
responders, possibly providing a protective effect to exceptional responders.
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Differential β Value Distribution
Among CpG sites that have a Δβ greater than 0.2, the typical group closely
resembles the normal beta value distribution, while the exceptional group is characterized
by a higher level of methylation. Nearly all (95%) of the differentially methylated CpG
sites and 100% of the differentially methylated promoters have a higher degree of
methylation in exceptional responders. Histograms and cumulative distribution plots
show a strong shift towards higher β values in exceptional responders, and the KS tests
indicate that this difference is statistically significant. This hypermethylation in
exceptional responders relative to typical responders and normal glial cells suggests an
increased level of transcriptional control that may confer a protective effect to exceptional
responders.
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CHAPTER 4
GENE EXPRESSION

Introduction
Gene Expression Microarrays
Gene expression levels can be assessed with multiple methods, but the gene
expression data in this study was generated with Affymetrix microarrays. This technology
enables the analysis of gene expression across the whole genome, including more than
45,000 probe sets to assess relative expression levels of more than 39,000 transcripts and
variants.63

Analysis Packages
Guanine Cytosine Robust Multi-Array Analysis (GCRMA) is a Bioconductor
package that performs normalization of microarrays. This tool implements a background
correction, followed by a normalization step to make measurements between different
arrays comparable, and then a summarization step to calculate a final expression
measurement. It also adjusts for background intensities including optical noise and nonspecific binding. It is an improvement upon the commonly used Robust Multi-Array
Analysis (RMA) algorithm, which does not adjust well for non-specific binding.64,65
Another tool utilized in this analysis is nsFilter, which is part of the genefilter
package and removes non-informative genes to reduce noise in the analysis. This tool
removes genes with little variation, consistently low signals, and control probe sets.66
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Limma is a software package for the analysis of gene expression. It utilizes linear
models to assess differential expression for a variety of technologies, including
microarrays, RNA sequencing, and quantitative PCR.67–69

Aberrant Gene Expression in GBM
The most well-known and most frequently occurring gene expression change in
GBM is the overexpression of EGFR. Other hallmark genes in GBM include IGFBP2
(insulin like growth factor binding protein 2), IGFBP5 (insulin like growth factor binding
protein 5), VEGF (vascular endothelial growth factor), VCAM1 (vascular cell adhesion
protein 1), MCM2 (minichromosome maintenance complex component 2), and TNC
(tenascin C).70

Methods
Affymetrix HT Human Genome U133 DNA microarray CEL files were obtained
from the GDC Legacy Archive on August 5, 2016 for 33 exceptional responders and 34
typical responders (Table 8). Three comparisons were performed: all exceptional
responders vs all typical responders, male exceptional responders vs male typical
responders, and female exceptional responders vs female typical responders. For each of
the three analyses, the arrays were normalized with GCRMA and filtering was performed
using the nsFilter function of the genefilter package in R. All experiments were performed
at the same location, which should minimize batch effects. Quality control tests, including
boxplots of probe intensities and density vs intensity histograms were generated in R
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Typical

Exceptional

Female

11

17

Male

23

16

Table 8: Sample number by sex and response group in gene expression analysis. Most patients
in both response groups had gene expression data available. The distribution of sexes between the
two groups is consistent with the full groups, with a male majority in the typical group and a
roughly equal number of males and females in the exceptional group.
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before and after normalization. Differential expression analysis was performed using
limma. A log2 fold change cutoff of 1.5 was applied to the resulting list of probes before
the multiple testing correction was performed. Only genes that were implicated in all
three analyses or in the full analysis but not in the sex-specific analyses were considered
to be significantly differentially expressed between the two response groups. Linear
regression models were generated with XLSTAT to investigate the prognostic value of
some of the differentially expressed genes. These models were generated using the full
TCGA GBM dataset, including 385 patients. Utilizing the same CEL files that were
analyzed with limma, version 2.2.4 of the Broad Institute’s Gene Set Enrichment Analysis
(GSEA) tool was used to detect enrichment of gene sets between exceptional and typical
responders as well as male and female patients. The CEL files were converted to Gene
Count files using the ExpressionFileCreator module found in GenePattern. Normalization
was performed with GCRMA in conjunction with quantile normalization. GSEA was run
using the c5.all.v6 database, with 1000 permutations performed using “phenotype” as the
permutation type.

Results
Quality control assessments indicate that all arrays included in the analysis were
normalized properly and none need to be excluded. Box plots of the log intensity
distributions for each array (Figure 9) are extremely consistent following normalization,
indicating that between-array comparisons can be made with this dataset without
removing any arrays. Density plots of log intensity distribution (Figure 10) also show very
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Figure 9: Quality control assessment by log intensity distributions. Log intensity distributions
were generated in R before normalization (top) and after normalization (bottom) to determine if
between-array comparisons could be made or if any arrays needed to be removed. The consistent
distributions following normalization indicate that all arrays in the analysis could be compared
and none needed to be removed.
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Figure 10: Quality control assessment by density plot. Density plots of log intensity distribution
were generated in R before normalization (top) and after normalization (bottom) to identify any
arrays with an abnormal distribution. Following normalization, all the arrays had consistent log
intensity distributions and none needed to be removed from the analysis.
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consistent distributions following normalization, meaning that there are no outliers that
need to be excluded.
The analysis identified 4 significantly differentially expressed genes (Table 9).
ETNPPL (ethanolamine-phosphate phospho-lyase) and SH3GL2 (SH3 domain containing
GRB2 like 2, endophilin A1) were more highly expressed in exceptional responders, while
CXCL8 (interleukin 8) and CCL20 (chemokine ligand 20) were more highly expressed in
typical responders. There were 13 additional genes determined to be significantly
differentially expressed in the full analysis, but they were all also identified in one sexspecific analysis and not the other. These were excluded from the final results because
they may only be present due to sex being a confounding variable.
Linear regression models indicate that CXCL8 is predictive of survival time.
Increased expression of CXCL8 is associated with reduced survival time. The overall
model is statistically significant (p < 0.001), as is the CXCL8 term (p < 0.001). The equation
for the model is: 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 𝑡𝑖𝑚𝑒 (𝑑𝑎𝑦𝑠) = 812 − 40.1 ∗ 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑠𝑖𝑔𝑛𝑎𝑙 𝑜𝑓 𝐶𝑋𝐶𝐿8.
GSEA identified 4 gene sets enriched in exceptional responders and 1 gene set
enriched in typical responders (Table 10). The leading edge analysis revealed which genes
contributed to the enrichment of which gene sets in the exceptional responders (Figure
11). NLGN1 and STXBP1 contributed to the enrichment of all four gene sets and RAB3A,
RIMS3, SNCA, SYN1, RAB5A, RAB3GAP1, and PFN2 contributed to the enrichment of
three of them. All of the other implicated genes were associated with only one or two of
the gene sets. There were no significantly enriched gene sets identified when the analysis
was divided by sex.
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Gene

log2FC
(all)

log2FC
(female)

log2FC
(male)

p value
(all)

p value
(female)

p value
(male)

ETNPPL

1.553

1.931

1.659

0.0225

0.0703

0.0560

SH3GL2

1.771

2.301

1.758

0.0018

0.0089

0.0210

CXCL8

-1.735
-1.863

-3.094
-2.345

-1.904

0.0038
0.0045

0.00076
0.0133

0.0330

CCL20

-1.751

-2.383

-1.520

0.0042

0.0155

0.0487

Table 9: Significantly differentially expressed genes. Four genes were determined to be
significantly differentially expressed between typical and exceptional responders following
multiple testing correction (q < 0.1) and comparison to the sex-specific analyses. Log2 fold change
(log2FC) and p values are shown for the full analysis and for each sex-specific analysis. ETNPPL
and SH3GL2 are more highly expressed in exceptional responders and CXCL8 and CCL20 are more
highly expressed in typical responders.
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Name

Enriched in

Normalized
Enrichment
Score

regulation of synaptic vesicle
transport

exceptional

2.062

p < 0.001

0.124

regulation of neurotransmitter
transport

exceptional

2.025

p < 0.001

0.113

positive regulation of calcium
ion dependent exocytosis

exceptional

2.008

p < 0.001

0.109

neurotransmitter secretion

exceptional

2.006

p < 0.001

0.078

negative regulation of
cytokine biosynthetic process

typical

-2.068

p < 0.001

0.154

p value

FDR q value

Table 10: Enriched gene sets identified by GSEA. GSEA identified five enriched gene sets, four
of which are enriched in exceptional responders.
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Figure 11: Leading edge analysis of gene sets enriched in exceptional responders. Leading edge
analysis of the four gene sets enriched in exceptional responders indicated which genes contributed
to each result. The color gradient indicates the range of expression values (red, pink, light blue, and
dark blue correspond to high, moderate, low, and lowest expression, respectively). Two genes
contributed to all four results and seven genes contributed to three of the four, but most of the
genes contributed to just one or two of the enriched gene sets.
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Discussion
Addressing the Confounding Variable
A majority of the genes identified as being significantly differentially expressed in
the full dataset were excluded because they were also present in the results of only one of
the sex-specific analyses and may only appear to be significant due to the confounding
variable of sex. In several of the cases, at least, this seems very likely. Some of the genes
excluded for potentially being the result of differential expression between males and
female include XIST, RPS4Y1, and DDX3Y. XIST is expressed in females as the major
effector of the X inactivation process, and RPS4Y1 and DDX3Y are both found on the Y
chromosome and should therefore only be expressed in males. That these were excluded
from the final results by the methodology for this analysis suggests that this method was
successful in controlling for sex-specific results.

Significantly Differentially Expressed Genes
The four genes included in the final results list are CXCL8, CCL20, ETNPPL, and
SH3GL2. CXCL8 is an angiogenic factor in GBM, gliomas, and many other cancers and
CCL20 promotes malignancy in various cancers and has been implicated in glioma.71–77
Both of those genes were overexpressed in typical responders relative to exceptional.
CXCL8 and CCL20 are often implicated in diseases together, particularly in colorectal
cancer, in which they synergize to promote a poor survival outcome via a collaborative
induction of the epithelial-mesenchymal transition.78 Overexpression of these two genes
are likely contributing to the poorer prognosis of typical responders. In vivo studies of
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overexpression of these genes in GBM cell lines would be necessary to confirm that they
contribute to a more tumorigenic phenotype.
The other two significant genes were more highly expressed in exceptional
responders. ETNPPL is a lyase that is downregulated in hepatocellular carcinoma, and
SH3GL2 is a positive prognostic factor in head and neck squamous cell carcinoma. 79
SH3GL2 is targeted by mir330, which promotes malignancy in GBM cell lines, suggesting
that reduced expression of SH3GL2 results in more aggressive tumors.80 The
overexpression of these two genes is consistent with a more positive prognosis.

CXCL8 is Predictive of Survival Time
Based on the established relationship between CCL20 and CXCL8 in the literature,
these two genes were investigated as possible prognostic factors for GBM with linear
regression models. While the term for CCL20 was not statistically significant in the model,
when it was removed and the model was regenerated with CXCL8 only, it was found to
be significantly predictive of survival. The equation for the model suggests that for every
one unit increase in CXCL8 expression, there is an associated 40 day reduction in survival.
CXCL8 is a chemokine and potent angiogenic factor that may contribute to
tumorigenesis81, so its overexpression in typical responders relative to exceptional
responders is indicative of more aggressive tumors in typical responders, which may
explain the significant association between higher CXCL8 expression and shorter survival
in the full GBM dataset.
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GSEA
GSEA identified 5 enriched gene sets, 4 of which were enriched in exceptional
responders and 1 of which was enriched in typical responders. The four gene sets enriched
in exceptional responders are all very similar and are related to synaptic transmission,
suggesting that exceptional responders have an increased ability to maintain synaptic
transmission functions and that it might be granting them some advantage over typical
responders.
Interestingly, 6 of the genes contributing to the enriched gene sets in exceptional
responders (STXBP1, DNM1, SYNJ1, KCNB1, PLCB1, and CACNA1A) are among a group
of genes that have been implicated in early infantile epileptic encephalopathy (EIEE)82, an
extremely debilitating disorder characterized by uncontrollable seizures and severe
mental retardation.83 Mutations in these genes are associated with EIEE, but it appears
that overexpression of these genes is associated with a positive prognosis in GBM. All of
these genes are associated with synaptic transmission.
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CHAPTER 5
miRNA EXPRESSION

Introduction
Micro RNAs (miRNAs) are a class of regulatory molecules that have been
implicated as important players in tumorigenesis.84 A subset of miRNAs have been found
to be consistently dysregulated in GBM (Table 11) and some of these can also be used to
predict prognosis or therapeutic response. Aberrant expression of these miRNAs can
impact tumorigenic pathways in GBM such as induction of angiogenesis, resistance to
apoptosis, and sustained proliferation signaling.85
The miRNA expression data for this study were generated with the Agilent
Human miRNA Microarray 8x15K platform. These microarrays contain probes with high
sensitivity and specificity for all human miRNAs reported in the Sanger miRBASE
database.86

Methods
Files containing the calculated expression values of 534 miRNAs for 38 typical and
34 exceptional responders (Table 12) were retrieved from the GDC Legacy Archive on
September 1, 2016. Welch’s unequal variances t-tests were performed for each miRNA to
identify which ones are significantly differentially expressed between the response
groups. The multiple testing correction was performed using the Benjamini-Hochberg
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Upregulated
miR-9

miR-10a

miR-10b

miR-15b

miR-17-5p

miR-25

miR-21

miR-26a

miR-92b

miR-93

miR-106a

miR-130a

miR-155

miR-182

miR-196b

miR-210

miR-221

miR-222

miR-296

miR-451

Downregulated
miR-7

miR-34a

miR-124*

miR-125b

miR-128*

miR-129-5p*

miR-132

miR-136

miR-137

miR-139-5p*

miR-146b

miR-153

miR-181*

miR-184

miR-218

miR-323

miR-326

miR-328

miR-495

Table 11: Consistently dysregulated miRNAs in glioblastoma. These miRNAs have been
established as frequently upregulated or downregulated in GBM 85 and were used as a guide to
reduce multiple testing in the analysis. miRNAs labeled with a * were not assessed by the arrays
in this study.
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Typical

Exceptional

Female

11

17

Male

27

17

Table 12: Sample number by sex and response group in miRNA analysis. Nearly all of the
patients in both response groups had miRNA expression data available. The distribution of sexes
in the two groups is similar to the full groups, with most a majority of typical responders being
male and an even number of males and females in the exceptional responders group.
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FDR method (q < 0.1). The t-tests and corrections were performed again on a reduced
dataset after the miRNA list was restricted to only those miRNAs that appear in Table 11.

Results
No miRNAs were significantly differentially expressed between typical and
exceptional responders following the multiple testing correction, even when multiple
testing was reduced by restricting the results to only miRNAs known to be consistently
dysregulated in GBM. Prior to correcting for multiple testing, there were 37 miRNAs with
p < 0.05 in the full dataset and 2 in the reduced dataset (Table 13).

Discussion
Although quite a few miRNAs have been associated with GBM, including some
that are specifically associated with prognosis or treatment response 85, no significantly
differentially expressed miRNAs were identified in this study. This does not necessarily
mean that the miRNAs analyzed are not important in GBM. They may be differentially
expressed in both response groups relative to normal expression, but simply not be
differentially expressed between the response groups themselves.
Several of the top results have previously been associated with GBM prognosis or
with prognosis and/or treatment response in other cancers. However, these results did
not reach statistical significance after a multiple testing correction was applied, so they
were not included in any downstream analyses.
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Hybridization REF

p value

hsa-miR-621
hsa-miR-490

0.0026
0.0070

hsa-miR-191

0.0094

hsa-miR-330

0.0097

hsa-miR-200b

0.0100

hsa-miR-128a

0.0102

hsa-miR-767-3p

0.0114

hsa-miR-574

0.0124

hsa-miR-200a

0.0154

hsa-miR-128b

0.0156

hsa-miR-510

0.0158

hsa-miR-367

0.0186

kshv-miR-K12-7

0.0192

hsa-miR-429

0.0199

hsa-miR-801

0.0224

hsa-miR-648

0.0233

hsa-miR-204

0.0242

hsa-miR-586

0.0243

hsa-miR-422a

0.0245

hcmv-miR-US5-1

0.0250

hsa-miR-222*

0.0258

hsa-miR-550

0.0305

hsa-miR-200a

0.0315

ebv-miR-BART17-5p

0.0324

kshv-miR-K12-4-3p

0.0330

hsa-miR-548c

0.0336

hsa-miR-603

0.0344

hsa-miR-339

0.0356

ebv-miR-BHRF1-2

0.0378

hsa-miR-604

0.0412

hsa-miR-296*

0.0415

hsa-miR-581

0.0416

hsa-let-7b

0.0434

hsa-miR-20a

0.0444

hsa-miR-19a

0.0455

hsa-miR-520a

0.0455

hsa-miR-345

0.0458

Table 13: Differentially expressed miRNAs. This includes the top results of the miRNA analysis
(all miRNAs with p < 0.05). miRNAs labeled with a * also appeared in the reduced analysis based
on the list in Table 10. None of these results reached statistical significance following a multiple
testing correction (q < 0.1).
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CHAPTER 6
PROTEIN EXPRESSION

Introduction
Reverse Phase Protein Array (RPPA) is a high throughput assay in which
antibodies are printed across slides to quantify the amounts of various proteins in
multiple samples simultaneously. This method allows for sensitive and accurate
quantification of proteins, including phosphoproteins, from a small amount of sample
material as long as high quality antibodies are available. The TCGA protein expression
data is generated by the MD Anderson RPPA Core Facility, which currently utilizes a
panel of 304 antibodies in its experimental protocol.87,88 The GBM dataset includes results
for 222 antibodies.

Methods
Files containing relative protein expression data were obtained from the GDC
Legacy Archive for 7 typical and 13 exceptional responders (Table 14) on September 24,
2016. Mann-Whitney U tests were performed for each of the 222 antibodies to identify
which proteins are significantly differentially expressed between the response groups.
The multiple testing correction was performed using the Benjamini-Hochberg FDR
method (q < 0.1).
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Typical

Exceptional

Female

2

6

Male

5

7

Table 14: Sample number by sex and response group in protein expression analysis. Very few
patients had protein expression data available. The sex distribution across response groups was
consistent with the distribution in the full groups, however.
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Results
No proteins were significantly differentially expressed between typical and
exceptional responders following the multiple testing correction. Without correcting for
multiple testing, there are five proteins with significant p values (p < 0.05). These proteins
are associated with the genes ITGA2, BCL2, BCL2A1, RPS6KB1, and RAD51 (Table 15).

Discussion
Unlike most of the other data types investigated in this work, the protein
expression arrays assess a relatively small number of data points. While most of the other
analyses were genome-wide, the protein expression data type includes results for just 222
antibodies. Being limited to this comparatively small panel substantially diminishes the
likelihood of identifying differential aberrations between typical and exceptional
responders for this data type, which may be part of the reason why no statistically
significant results were identified.
The protein expression analysis was also characterized by a much smaller sample
size than most of the other analyses, with only 7 typical and 13 exceptional responders.
Perhaps with a larger sample size, there would be more definitive and statistically
significant results.
Of the top results, both BCL2 (B-cell lymphoma 2) and RAD51 (RAD51
recombinase) have been associated with GBM prognosis.89,90 However, because these
results did not reach statistical significance following the multiple testing correction, they
were not included in any downstream analyses.
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Antibody

Gene

p value

CD49b-M-V

ITGA2

0.0027

Bcl-2-M-V

BCL2

0.0198

Bcl2A1-R-V

BCL2A1

0.0252

P70S6K-R-V

RPS6KB1

0.0324

RAD51-M-C

RAD51

0.0329

Table 15: Differentially expressed proteins. This includes the top results of the protein expression
analysis (all antibodies with p < 0.05). The gene associated with the protein that each antibody
labels is listed. None of these results reached statistical significance following a multiple testing
correction (q < 0.1).
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CHAPTER 7
INTEGRATION AND PATHWAY ANALYSES

Introduction
Pathway analysis techniques are used to help interpret the results of omics studies
by identifying genes that play a role in the same cellular process, disease, signaling
pathway, or other biological pathway. This can provide a global perspective on the results
generated and can help with understanding the results in terms of biological relevance. 91
Two commonly utilized pathway analysis tools are Gene Ontology (GO)92 and the Kyoto
Encyclopedia of Genes and Genomes (KEGG).93
The GO project is a tool used to describe gene products in terms of gene product
properties, including molecular functions and associated biological processes.92 ClueGO is
a Cytoscape plug-in that utilizes Cytoscape’s visualization capabilities to generate a GO
term network. This tool includes a Fusion feature to reduce redundancy by combining
related GO terms into the most representative term.94
KEGG is a comprehensive database that represents the current knowledge of
molecular interaction and reaction networks and is usually utilized to understand
biological pathways and systems, especially in large-scale genomic datasets. This resource
can be used to derive a systems-level understanding of molecular-level information and
gain insight into the functional significance of the results of high-throughput analyses.93
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Methods
In order to integrate the results from the individual analyses of this study and
derive some functional significance, genes contributing to enriched gene sets,
differentially expressed or methylated genes, and genes with differential copy number
gains/losses (Table 16) were combined and used as the input for GO and KEGG analyses
for each response group. The GO analysis was performed using the Cytoscape plug-in
ClueGO with all four GO types selected, GO Term Fusion enabled, and results restricted
to pathways with p<0.05 after Benjamini-Hochberg FDR multiple testing correction. All
other parameters were left as the default. In the KEGG analysis, only pathways with at
least 3 associated genes were included for further consideration. Heat maps were
generated with Heatmapper. Both Pearson (r) and Spearman (ρ) correlation coefficients
were calculated to assess the degree and direction of correlation between gene expression
and copy number as well as gene expression and methylation.

Results
Three enriched GO terms were identified from the gene list that is upregulated in
typical responders (Table 17). These include regulation of lipid storage, regulation of
interleukin-10 production, and regulation of cytokine biosynthetic process. The
exceptional responders, however, had 105 enriched GO terms which ClueGO GO Term
Fusion reduced to 12 enriched GO terms (Table 18 and Figure 12). Almost all of the
enriched GO terms are associated with synapse formation or function.
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Copy Number

Methylation

Gene Expression

GSEA

Typical Responders

Exceptional Responders

VSTM2A
LOC285878
OR4M2
OR4N4

CDKN2A-AS1
CDKN2A

SLC15A3
TTC12
LRRC8E
SUSD3
LRRC61

CXCL8
CCL20

LAG3
SFTPD
INHBA
TRIB2
KLF4
NMI
NFKB1
INHBB
IL6
RNF128
BCL3

ETNPPL
SH3GL2

NLGN1
STXBP1
DNM1
PINK1
SYNJ1
CDK5
SCAMP5
CACNA1I
SYT1
KCNB1
PLCB1
CDK5R2
NOS1
CPM6B
TOR1A
CAMK2A

CACNA1A
RIMS1
KCNMB4
SNCG
MEF2C
SNCAIP
SYT11
ACCN2
NF1
RAB3A
RIMS3
SNCA
SYN1
RAB5A
RAB3GAP1
PFN2

Table 16: Significantly upregulated genes across all analyses. Genes with statistically significant
alterations between the two response groups are included. “Upregulated” for each data type is
defined as follows: copy number gains, lower promoter methylation, increased gene expression,
and enrichment in GSEA. The only significant results not included are differentially methylated
CpG sites. Only promoters were included from the methylation results because promoter
methylation is consistently negatively correlated with gene expression, while methylation of sites
in other regions is not.
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GO Term

p value

Associated Genes

regulation of cytokine
biosynthetic process

1.50x10-22

BCL3, CCL20, IL6, INHBA, INHBB, KLF4,
LAG3, NFKB1, NMI, RNF128, SFTPD, TRIB2

regulation of interleukin-10
production

1.50x10-05

BCL3, IL6, TRIB2

regulation of lipid storage

1.90x10-05

IL6, NFKB1, VSTM2A

Table 17: Significantly enriched GO terms in typical responders. Three GO terms were identified
as significantly enriched in typical responders following Benjamini-Hochberg FDR multiple testing
correction. The p values are adjusted. Each group identified with GO Term Fusion only has one
associated GO term.
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GO Term

p value

Associated Genes
ASIC1, CACNA1A, CAMK2A, CDK5,
KCNMB4, MEF2C, NF1, NLGN1, PFN2,
RAB3A, RAB3GAP1, RAB5A, RIMS1, RIMS3,
SNCA, SNCAIP, SNCG, STXBP1, SYN1, SYNJ1,
SYT1, SYT11, TOR1A
ASIC1, CACNA1A, CAMK2A, KCNMB4,
MEF2C, NF1, NLGN1, NOS1, PFN2, RAB3A,
RAB3GAP1, RAB5A, RIMS1, RIMS3, SNCA,
SNCAIP, SNCG, STXBP1, SYN1, SYT11, TOR1A
CACNA1A, CDK5, NLGN1, PFN2, RAB3A,
RAB3GAP1, RAB5A, RIMS1, RIMS3, STXBP1,
SYN1, SYNJ1, SYT1, SYT11

presynaptic process
involved in chemical
synaptic transmission

2.9x10-31

regulation of
neurotransmitter transport

4.6x10-29

synaptic vesicle exocytosis

4.9x10-27

regulation of synaptic
vesicle recycling

3.0x10-24

CDK5, DNM1, NLGN1, SNCA, SYT11, TOR1A

regulation of synaptic
vesicle exocytosis

6.1x10-22

NLGN1, PFN2, RAB3A, RAB3GAP1, RAB5A,
RIMS1, RIMS3, STXBP1, SYN1

neuron-neuron synaptic
transmission

2.5x10

regulation of synaptic
plasticity

1.2x10-15

acid secretion

1.5x10-15

CACNA1A, NF1, RAB3A, RAB3GAP1, RIMS1,
SNCA, STXBP1, SYT1

positive regulation of
synaptic transmission

2.1x10-15

NF1, NLGN1, PINK1, RAB3GAP1, RIMS1,
SNCA, SYT1, SYT11

regulation of amine
transport

6.8x10-13

CACNA1A, KCNB1, PINK1, RAB3GAP1,
SNCA, SNCG, SYT1, TOR1A

positive regulation of
protein targeting to
membrane

2.3x10-5

CACNA1A, CDK5, KCNB1

voltage-gated calcium
channel complex

5.0x10-5

CACNA1A, CACNA1I, NOS1

-21

CACNA1A, CDK5, DNM1, MEF2C, NF1,
NLGN1, PINK1, RAB3GAP1, SNCA, STXBP1,
SYT1, TOR1A
CAMK2A, CDK5, KCNB1, MEF2C, NF1,
NLGN1, RAB3A, RAB3GAP1, SNCA, STXBP1,
SYT11

Table 18: Significantly enriched GO terms in exceptional responders. Twelve GO term groups
were identified as significantly enriched in exceptional responders following Benjamini-Hochberg
FDR multiple testing correction. The p values are adjusted and based on the groups identified by
GO Term Fusion, not individual GO terms.
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Figure 12: GO Term Fusion results in exceptional responders. The 12 GO term groups identified
with GO Term Fusion are associated with 105 enriched GO terms. The pie graph indicates the
number of GO terms included in each group.
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KEGG analysis for the typical responders identified quite a few pathways based
on 5 subsets of the upregulated genes (Table 19). The top results are the IL-17 signaling
pathway and the TNF signaling pathway. The KEGG analysis for the exceptional
responders gene list yielded 5 enriched pathways, including synaptic vesicle cycle, MAPK
signaling pathway, calcium signaling pathway, Alzheimer’s disease, and Parkinson’s
disease (Table 20).
The relationships between the data types with significant results (copy number,
methylation, and gene expression) was further investigated with heat maps and
correlation analyses (Figure 13 and Table 21). Among only the genes identified in Table
16, there is a weak to moderate positive correlation between copy number and gene
expression for both response groups, with similar coefficients resulting from both the
Pearson and Spearman tests. A strong negative correlation between methylation and gene
expression was indicated by both correlation tests for that same gene list. When
comparing methylation and gene expression genome-wide, there is a moderate to strong
negative correlation for both the typical responders (r = -0.356, ρ = -0.363) and the
exceptional responders (r = -0.365, ρ = -0.387).

Discussion
Spearman versus Pearson Correlation
Both the Spearman and the Pearson correlation methods are utilized in the
literature to assess the relationship between methylation and gene expression, but most
studies include only one or the other. The Pearson test is more suited to continuous
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Genes

Pathways

CCL20
IL6
CXCL8

IL-17 signaling pathway

NFKB1
BCL3
CCL20
IL6

TNF signaling pathway

NFKB1
Pathways in cancer
Non-alcoholic fatty liver disease
Chagas disease
Legionellosis
Pertussis
Salmonella infection
IL6

Amoebiasis

CXCL8

Kaposi’s sarcoma-associated herpesvirus infection

NFKB1

Transcriptional misregulation in cancer
Toll-like receptor signaling pathway
Cellular senescence
Hepatitis B
NOD-like receptor signaling pathway
AGE-RAGE signaling pathway in diabetic complications
Influenza A

CCL20
IL6
CXCL8

Rheumatoid arthritis
Cytokine-cytokine receptor interaction

CCL20
CXCL8

Chemokine signaling pathway

NFKB1
Table 19: Significantly enriched KEGG pathways in typical responders. KEGG analysis
identified multiple pathways enriched in typical responders that are associated with five groups
of genes.
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Genes

Pathways

CACNA1A
DNM1
RAB3A
RIMS1

Synaptic vesicle cycle

STXBP1
SYT1
CACNA1A
CACNA1I
MEF2C

MAPK signaling pathway

NF1
CACNA1A
CACNA1I

Calcium signaling pathway

NOS1
CDK5
NOS1

Alzheimer’s disease

SNCA
PINK1
SNCA

Parkinson’s disease

SNCAIP
Table 20: Significantly enriched KEGG pathways in exceptional responders. KEGG analysis
identified enriched pathways in exceptional responders.
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Figure 13: Heat maps for methylation and gene expression. Heat maps were generated with all
genes from Table 15 that had data for both methylation and gene expression. Heat maps for both
typical and exceptional responders indicate a negative correlation between methylation and gene
expression. This correlation appears to be stronger in the list of genes that are upregulated in
typical responders.
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Typical

Copy Number & Gene Expression

Methylation & Gene Expression

Pearson (r)

0.2333

-0.4484

Spearman (ρ)

0.2496

-0.5174

Exceptional

Copy Number & Gene Expression

Methylation & Gene Expression

Pearson (r)

0.2120

-0.6065

Spearman (ρ)

0.2370

-0.5857

Table 21: Correlation between copy number/methylation and gene expression. Each correlation
test was performed for the list of genes in Table 15, excluding those that did not have data available
for the relevant data type. The results indicate a weak to moderate positive correlation between
copy number and gene expression and a strong negative correlation between methylation and gene
expression.
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variables, while the Spearman test is more suited to categorical variables.95 β values are a
continuous variable, so the Pearson test seems more appropriate, but the Spearman test
generally gives results of a larger magnitude for correlations between methylation and
gene expression, which is perhaps why it is used so often for those types of studies. It is
possible that the Spearman test typically gives better results because methylation may be
more categorical than continuous in reality, functioning more like an on/off switch than
in a linear manner. In any case, both tests were utilized in this study to provide a clearer
understanding of the relationship between methylation and gene expression for this
dataset.

Enriched GO Terms
The main contributors to the enriched GO terms for typical responders are IL6
(interleukin 6), which is associated with all three terms, and BCL3 (B-cell lymphoma 3),
NFKB1 (nuclear factor kappa B subunit 1), and TRIB2 (tribbles pseudokinase 2), which are
associated with two terms each. All four of these genes are associated with NF-κB, a
protein complex that acts as a transcription factor and plays a role in cytokine production
and cell survival. NF-κB is constitutively active in many cancers, causing cells to
proliferate and protecting them from death by apoptosis.96 Activation of NF-κB in GBM
has been shown to contribute to angiogenesis and temozolomide resistance. 97 Typical
responders are characterized by a significant upregulation of key players in NF-κB
signaling relative to exceptional responders, which may explain their poorer prognosis.
An alternative way to view this is that exceptional responders are characterized by less
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NF-κB signaling, allowing them to remain more sensitive to temozolomide and resulting
in longer survival times.
Nearly all of the GO terms enriched in exceptional responders are associated with
synaptic plasticity. The process of autophagy intersects with many of the pathways
known to underlie synaptic plasticity, and it has been proposed that autophagy plays a
direct role in synaptic plasticity.98,99 Perhaps the tumors of exceptional responders are
more susceptible to cell death by autophagy, or some other consequence of increased
synaptic plasticity may confer some advantage.
SNCA (synuclein alpha), which is associated with eight of the enriched GO terms,
may be of particular interest as it has been shown to increase the vulnerability of the GBM
cell line U373 to cell death.100 SYT11 is of interest as well, as its depletion is known to block
autophagy.101 The upregulation of SYT11 in exceptional responders may allow autophagy
to occur.

Enriched KEGG Pathways
The top enriched pathways in typical responders are IL-17 and TNF. IL-17 is a proinflammatory pathway that can contribute to tumor progression and metastasis as well as
resistance to chemotherapy.102 TNF activates the NF-κB pathway and can promote cell
growth, proliferation, invasion, and angiogenesis.103 Enrichment of either of these
pathways could contribute to the poorer prognosis seen in the typical response group.
Cytokine-cytokine receptor interaction and chemokine signaling pathways are also
implicated, much like in the GO analysis.
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In exceptional responders, synaptic transmission appears again, along with MAPK
signaling, calcium signaling, Parkinson’s disease, and Alzheimer’s disease, all of which
are related to synaptic plasticity.104–107 Parkinson’s disease pathways being enriched in
exceptional responders is of particular interest, as several epidemiological studies indicate
an inverse association between cancer risk and Parkinson’s disease.108 Like synaptic
plasticity, the enrichment of Parkinson’s and Alzheimer’s pathways also implicates
autophagy since both of those diseases are characterized by neurodegeneration in which
autophagy plays a role.109,110 Perhaps the upregulation of these pathways in exceptional
responders makes the tumors more susceptible to autophagic cell death.

Correlation Results
No gene was identified as statistically significant among the results of more than
one data type. However, the trends seem to match and the correlation results corroborate
this. In many cases, the r and ρ values reported in this study would be considered weak
to moderate, but in the case of the correlation between methylation and gene expression,
correlation coefficients with the magnitudes identified in this study are quite good.
Typically, correlation coefficients for methylation and gene expression are rather modest,
right around -0.3, which has been attributed to noise, sample heterogeneity, and other
regulatory events besides methylation.111 This means that the relationship between
methylation and gene expression in this study is a strong negative correlation, as the
correlation coefficients are of a larger magnitude than 0.3, especially when the gene list
being assessed is narrowed to only the significant results list. The correlation between
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copy number and gene expression is not as strong, but this is not surprising given the
large number of other regulatory mechanisms that could be affecting gene expression, as
well as the fact that nearly all of the significant copy number aberrations were only gains
or losses and not whole duplications or deletions.
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DISCUSSION

Sex as a Confounding Variable
Although sex was a confounding variable for survival between the typical and
exceptional response groups, it was not confounding in the full dataset. Although the
incidence of GBM is higher in males, sex has not been found to be predictive of prognosis
or survival in GBM.112 For these reasons, it seems likely that the identification of sex as a
confounding variable is an artifact or just occurred by chance for this particular dataset.
Although it is unlikely that sex is truly predictive of survival in GBM, the
distribution of sexes between the two response groups was significantly skewed
nonetheless, and this had to be accounted for. When possible, this problem was addressed
by performing sex-specific analyses in addition to the full analysis of typical versus
exceptional responders (as in the copy number and expression analyses), and then only
results identified in all three analyses or only in the full analysis and not in the sex-specific
analyses were included in the final results. When there was not a sufficient number of
samples available to perform sex-specific analyses (as in the methylation analysis), sex
chromosomes were excluded from the analysis. These efforts seem to have been successful
in controlling for the differential distribution of sex in the response groups. Prior to
performing the methods to control for sex, many results were genes on the X or Y
chromosome or were otherwise associated with sex. This was particularly true in the
methylation analysis, in which most of the results were on the X chromosome prior to
controlling for sex. This was likely due to X inactivation in females, which is the process
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by which one X chromosome is silenced via heavy methylation.113 After the methods to
control for the differential distribution of sexes were applied, the final results for all the
data types were largely biologically relevant and not associated with any sex-specific
biological processes.

Data Types with No Significant Results
Of all the data types analyzed, the miRNA expression analysis and the protein
expression analysis were the only ones that did not yield any significantly differentially
expressed results. In the case of protein expression, this is likely largely due to both the
small sample size and the relatively small number of proteins assessed. While RPPA
assesses expression of quite a large number of proteins compared to other techniques such
as western blots, it is still only a very small fraction of the proteome (222 antibodies). The
only overlap between the significant results from other data types and the list of proteins
assessed by RPPA is CDKN2A, which had a greater magnitude of copy number loss in
typical responders. Protein expression results indicate that typical responders had a lower
mean relative expression of CDKN2A (0.496 for typical and 1.095 for exceptional), as
expected based on the copy number analysis, but this result was not statistically
significant. Between the low degree of overlap and the small number of patients for whom
protein expression data were available, it is not surprising that no significant results were
identified. As for the miRNA expression, the sample size was suitable and the number of
miRNAs assessed was reasonable, and yet no significant results were identified. While it
has been established that aberrant expression of a variety of miRNAs relative to normal
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expression is characteristic of GBM overall, it is possible that these are simply not
differentially expressed between the response groups in this dataset.

Trend of Disorder in Typical Responders
The results from several analyses suggest that typical responders are characterized
by a loss of transcriptional control and aberrations of a greater magnitude than
exceptional responders. The copy number analysis revealed that while most copy number
alterations are consistent across both response groups, the magnitude is consistently
larger in the typical responders. Methylation levels at CpG sites with a large degree of
variation between the response groups are almost invariably lower in typical responders,
suggesting that exceptional responders have increased gene silencing and transcriptional
control. While both response groups tend to be characterized by many of the same
alterations, the changes tend to be more severe in typical responders. The somewhat less
severe alterations in exceptional responders may be contributing to their better prognosis.

Correlation Trends
No single gene was identified as statistically significant in more than one data
type. However, the trends for most of the significant results are concordant. For example,
genes with significantly higher promoter methylation tend to have lower expression
levels even though the expression comparison does not reach statistical significance.
Genes with copy number gains tend to have higher expression, genes with copy number
losses tend to have lower expression, and so on. The negative correlation between
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methylation and gene expression among the significant results list is particularly
convincing, with r and ρ values ranging from -0.4484 to -0.6065, indicating a strong
relationship between increased methylation and reduced gene expression among genes
that are altered between typical and exceptional responders.

Frequently Affected Pathways and Biological Processes
NF-κB
NF-κB was determined to be upregulated in typical responders relative to
exceptional responders in several analyses. Four of the five groups of genes associated
with enriched KEGG pathways in typical responders include NFKB1, a key player in the
NF-κB pathway. One of these enriched pathways is the TNF signaling pathway, which
activates NF-κB signaling, resulting in proliferation and protection from death by
apoptosis.103 NFKB1 was also an important player in two of the three enriched GO terms
in typical responders. Several other genes associated with NF-κB signaling were present
in the significant results, including IL6, BCL3, and TRIB2. Enrichment of this pathway in
typical responders may be partially responsible for their worse prognosis. Upregulation
of the NF-κB pathway is common in many cancers, including GBM, so perhaps a better
way to view this result is that exceptional responders tend to have less upregulation of
NF-κB than most GBM patients, providing them with a survival benefit.
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Synaptic Plasticity
The top KEGG pathway result, nearly all of the GO terms, and all of the GSEA
gene sets enriched in exceptional responders are directly related to synaptic plasticity,
which is the ability of neurons to change the quantity and strength of their synapses.
Astrocytes are heavily involved in this process.114 Autophagy pathways and synaptic
plasticity pathways have a lot of overlap, and it has been proposed that autophagy plays
a direct role in synaptic plasticity.98,99 Perhaps the upregulation of genes related to synaptic
transmission in exceptional responders leaves their tumor cells more susceptible to
autophagy. Glioblastoma cells are more likely to respond to autophagy-inducing
therapies than to apoptosis-inducing therapies115, and it is possible that this characteristic
of expectational responders increases this positive response even further. It may also be
the case that some other aspect of synaptic transmission and synaptic plasticity confers a
benefit to exceptional responders.

Neurodegenerative Diseases
Both Alzheimer’s disease and Parkinson’s disease pathways were enriched in
exceptional responders based on the KEGG analysis. Both of these diseases are
characterized by cell death through autophagy and/or apoptosis.109,110 Some studies
indicate that higher risk of Parkinson’s disease is inversely associated with cancer risk.108
While activation of these pathways is certainly detrimental in neurodegenerative diseases,
in cancer it may result in increased sensitivity to treatment. Tumors of exceptional
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responders with upregulation of these pathways may retain the ability to undergo cell
death in response to treatment, granting exceptional responders a better prognosis.

Cytokine Signaling
Cytokines are a group of small proteins that are important in cell signaling and are
especially important in the immune system. Pro-inflammatory cytokines are known to
promote cancer cell proliferation in many cases.116 Several pro-inflammatory cytokines
and associated pathways were implicated in typical responders throughout this study,
including IL6, CCL20, CXCL8, TNF signaling, and IL-17 signaling. The top enriched GO
term in typical responders was the regulation of cytokine biosynthetic processes and
enriched KEGG pathways in typical responders included cytokine-cytokine receptor
interaction and chemokine signaling pathway, in addition to the aforementioned TNF and
IL-17 signaling pathways. CXCL8 and CCL20 are perhaps the most prominent of these
results, as they were the only two genes with significantly higher expression in typical
responders compared to exceptional, and at least one of them is present in every group of
genes associated with the enriched KEGG pathways in typical responders. CXCL8 was
also found to be predictive of survival outcome in the full TCGA GBM dataset of 408
patients, with increased expression associated with significantly shorter survival times.
Typical responders are characterized by upregulation of pro-inflammatory cytokine
signaling, and exceptional responders do not share this trait. This lack of proinflammatory signaling in exceptional responders may give them a better prognosis.
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Final Remarks
The significant results generated in the copy number, methylation, gene
expression, and pathway analyses conducted in this study have provided some insight
into the molecular differences between typical and exceptional responders in GBM.
Upregulated pathways and processes in typical responders are consistently associated
with more aggressive tumor phenotypes that may be partially responsible for the poor
response to treatment that most GBM patients exhibit. Upregulated pathways and
processes in exceptional responders may indicate that the small number of patients who
respond very well to treatment have tumors that have retained the ability to undergo cell
death by autophagy, which may make the standard GBM treatment of temozolomide
more effective for this group.
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